ABSTRACT
BACKGROUND: Cellulite is a serious cosmetic concern for most of the 90% of women affected by it. OBJECTIVE: To assess the clinical efficacy of a complex integral anti-cellulite gel. METHODS: This double-blind, randomized, placebo-controlled study involved 44 healthy women, aged 25-55 years. Subjects had a normal to slightly overweight body mass index and presented slight to moderate cellulite on their thighs, buttocks, and/or hips at baseline. Subjects were randomly assigned to either the treated or placebo group and accordingly applied the active product or placebo on their hips, stomach, buttocks, and thighs, twice daily for 3 months. Skin tonicity, orange-peel aspect, and stubborn cellulite were assessed at day 0, 28, 56, and 84. A self-evaluation questionnaire was completed by all volunteers. RESULTS: At the end of the study, an average of 81% of the subjects applying the active product presented improvement in their cellulite condition versus 32% for the placebo group (all descriptors and sites combined). At day 84, skin tonicity, orange-peel appearance, and stubborn cellulite were improved in a significant manner (P<0.05) over placebo, on all studied areas. Skin tonicity improved on average by +41% for buttocks, +35% for hips, and +31% for thighs. Orange peel appearance was reduced on average by -25% for buttocks, -22% for hips, and -22% for thighs. Stubborn cellulite was reduced on average by -19% for buttocks, -24% for hips, and -22% for thighs. Circumference measurements decreased in a significant manner (P<0.05) over placebo, for the abdomen (average value of -1.1 cm) and thighs (average value of -0.8 cm). The product was well tolerated and perceived by the volunteers themselves as better performing than placebo on all criteria. CONCLUSION: All results validate the efficacy of the present integral formulation to significantly reduce signs of cellulite and reshape the silhouette.
ABSTRACT
BACKGROUND: Skin redness is a common cosmetic concern affecting predominantly fair-skin individuals and often leading to rosacea. On the basis of the current scientific knowledge of the physiological mechanisms underlying the problem, a complex and integral skin care serum (100RXED2025) was developed and tested clinically for efficacy. METHOD: Forty-five healthy men and women volunteers, age 30-65, were recruited. All subjects had fair skin (phototype I, II, or III) and presented some degree of skin redness with telangiectasia on the cheeks, the nose, or the nose sides, at baseline. In the course of this open label study, subjects applied the test product on their face, twice daily for 56 days. For each subject, skin redness was evaluated through colorimetric and visual analysis of photographs taken under cross-polarized light at T = 28 (week 4) and T = 56 (week 8), then compared to baseline measurements obtained at day 0. RESULTS: Forty-four volunteers completed the study. On visual evaluation, skin redness had decreased in average by 32.2% at T = 28 (P < 0.001) and by 48.0% at T = 56 (P < 0.001). Importantly, 91% of the subjects showed improvement of skin redness at T = 28, reaching 100% at T = 56. Colorimetric analysis gave an average reduction in redness of 11.6% at T = 28 (P < 0.001) and 13.7% at T = 56 (P < 0.001). CONCLUSION: The anti-redness efficacy of the test product was demonstrated after 28 days with further increase following 56 days of application.
